Stock IMM IMMUPHARMA PLC
Add to a list
To use this feature you must be a member
Log inSign up

Financials ImmuPharma plc

Equities

IMM

GB0033711010

Biotechnology & Medical Research

Market Closed - London S.E.
Other stock markets
 11:35:15 2024-04-26 am EDT 		5-day change 1st Jan Change
2.14 GBX 0.00% Intraday chart for ImmuPharma plc -8.94% +28.37%
Apr. 02 Immupharma jumps amid new IP strategy for P140 technology platform AN
Apr. 02 ImmuPharma plc Initiates New Intellectual Property Strategy to Significantly Enhance the Patent Life and Commercial Value for Its P140 Technology Platform CI

Valuation

Fiscal Period: December 2017 2018 2019 2020 2021 2022
Capitalization 1 225.3 16.39 26.78 33.4 16.51 6.135
Enterprise Value (EV) 1 222.8 11.6 25.44 28.18 14.87 5.467
P/E ratio -35.8 x -2.26 x -4.01 x -3.89 x -2.03 x -1.46 x
Yield - - - - - -
Capitalization / Revenue 1,497 x 202 x 344 x 264 x 140 x -
EV / Revenue 1,481 x 143 x 326 x 223 x 126 x -
EV / EBITDA -31.4 x -1.46 x -4.11 x -5.2 x -2.95 x -1.88 x
EV / FCF -218 x -4.22 x -7.29 x -19 x -8.31 x -2.99 x
FCF Yield -0.46% -23.7% -13.7% -5.26% -12% -33.5%
Price to Book 63 x 2.15 x 5.08 x 3.46 x 4.26 x 2.43 x
Nbr of stocks (in thousands) 132,523 139,467 167,361 250,221 250,221 333,403
Reference price 2 1.700 0.1175 0.1600 0.1335 0.0660 0.0184
Announcement Date 5/25/18 6/3/19 4/30/20 4/29/21 5/24/22 6/6/23
1GBP in Million2GBP
Estimates

Income Statement Evolution (Annual data)

Fiscal Period: December 2017 2018 2019 2020 2021 2022
Net sales 1 0.1505 0.0813 0.0779 0.1267 0.1184 -
EBITDA 1 -7.096 -7.947 -6.194 -5.418 -5.046 -2.911
EBIT 1 -7.234 -8.08 -6.282 -5.589 -5.16 -3.029
Operating Margin -4,807.88% -9,941.04% -8,061.14% -4,412.7% -4,359.84% -
Earnings before Tax (EBT) 1 -6.997 -7.955 -6.744 -7.246 -8.941 -4.456
Net income 1 -6.223 -7.207 -6.124 -6.86 -8.174 -3.807
Net margin -4,136.06% -8,866.22% -7,858.31% -5,415.72% -6,906.55% -
EPS 2 -0.0475 -0.0519 -0.0399 -0.0343 -0.0325 -0.0126
Free Cash Flow 1 -1.021 -2.747 -3.491 -1.483 -1.79 -1.83
FCF margin -678.79% -3,379.38% -4,479.68% -1,171.12% -1,512.14% -
FCF Conversion (EBITDA) - - - - - -
FCF Conversion (Net income) - - - - - -
Dividend per Share - - - - - -
Announcement Date 5/25/18 6/3/19 4/30/20 4/29/21 5/24/22 6/6/23
1GBP in Million2GBP
Estimates

Balance Sheet Analysis

Fiscal Period: December 2017 2018 2019 2020 2021 2022
Net Debt 1 - - - - - -
Net Cash position 1 2.47 4.79 1.34 5.22 1.65 0.67
Leverage (Debt/EBITDA) - - - - - -
Free Cash Flow 1 -1.02 -2.75 -3.49 -1.48 -1.79 -1.83
ROE (net income / shareholders' equity) -136% -129% -95% -91.9% -116% -110%
ROA (Net income/ Total Assets) -77.1% -73.9% -54.3% -41.8% -38.1% -38%
Assets 1 8.071 9.757 11.28 16.41 21.43 10.03
Book Value Per Share 2 0.0300 0.0500 0.0300 0.0400 0.0200 0.0100
Cash Flow per Share 2 0.0200 0.0400 0.0100 0.0200 0.0100 0
Capex 1 0.03 0.1 0.11 0.36 0.05 0.11
Capex / Sales 16.94% 126.57% 137.45% 284.44% 43.04% -
Announcement Date 5/25/18 6/3/19 4/30/20 4/29/21 5/24/22 6/6/23
1GBP in Million2GBP
Estimates

EPS & Dividend

Year-on-year evolution of the PER

Change in Enterprise Value/EBITDA

Annual profits - Rate of surprise

Company calendar

Sector Other Biotechnology & Medical Research

1st Jan change Capi.
IMMUPHARMA PLC Stock ImmuPharma plc
+28.37% 11.1M
IQVIA HOLDINGS INC. Stock Iqvia Holdings Inc.
+1.51% 42.75B
LONZA GROUP AG Stock Lonza Group AG
+49.22% 41.61B
MODERNA, INC. Stock Moderna, Inc.
+8.57% 41.34B
CELLTRION, INC. Stock Celltrion, Inc.
-12.36% 26.59B
ICON PUBLIC LIMITED COMPANY Stock ICON Public Limited Company
+8.92% 25.49B
ALNYLAM PHARMACEUTICALS, INC. Stock Alnylam Pharmaceuticals, Inc.
-25.13% 18.12B
MEDPACE HOLDINGS, INC. Stock Medpace Holdings, Inc.
+29.17% 12.24B
CHARLES RIVER LABORATORIES INTERNATIONAL, INC. Stock Charles River Laboratories International, Inc.
-3.12% 11.76B
UNITED THERAPEUTICS CORPORATION Stock United Therapeutics Corporation
+6.35% 11B
Other Biotechnology & Medical Research
  1. Stock Market
  2. Equities
  3. IMM Stock
  4. Financials ImmuPharma plc